Allergan’s New Age-Defying Injectable: The Next Generation


*For medical regulatory purposes we are unable to mention the brand name of this treatment. Ask your doctor for more information on this new injectable skin product from Allergan*

Allergan Pharmaceuticals South Africa is proud to announce its entry into the skin quality category, with the launch of a new injectable product using VYCROSS® technology for use on the face, neck, décolletage and hands.

A new innovation for skin quality

The new HA injectable treatment delivers improvements in skin smoothness (absence of fine lines), hydration and elasticity – and is designed to last for up to nine months with just one treatment.

Since this innovative product aims to deliver effective results, it eliminates the need for multiple treatments. It should be injected intradermally and can be used to treat the face, neck, décolletage and hands. The product additionally contains an anaesthetic to enhance patient comfort.

Dr Patricia Ogilvie, key clinical trialist and leading Dermatologist in Germany, says: “This new innovation answers a real need for a treatment that delivers a healthy-looking glow. Combined with the fact that only one treatment is needed to achieve results, this product will be a game changer in my clinic. I believe that great skin can have a profound impact on patients’ everyday lives – in particular their confidence. It goes far beyond aesthetics – when a patient is happy with how they look on the outside, this affects how they feel on the inside. The new Allergan product is a genuinely innovative treatment option that I’m excited to be able to offer to my patients.”


Demonstrated efficacy

In a clinical trial of 131 patients1, the clinical study showed an improvement in skin quality at one, four and six months. One month after treatment, 96% of patients’ cheeks were smoother (investigator assessment)1 and 91% of patients reported they were more satisfied with their skin.2 Results were sustained at six months, where patients reported that they continued to see significant improvements in skin hydration and were satisfied with their skin. The final study results will be available in April 2017.

As with other medical aesthetic treatments, patients reported adverse events including bruising and pain at the injection site. However, this new product was well tolerated and demonstrated an acceptable safety profile, with 95% of patients being able to return to social engagements one day after treatment.

*For medical regulatory purposes we are unable to mention the brand name of this treatment. Ask your doctor for more information on this new injectable skin product from Allergan*


Training programs

Allergan is strongly committed to the health, safety and well-being of the practitioners and patients who put their trust in their products. As part of the Company’s ongoing commitment to medical education, Allergan is now offering training programs for appropriate healthcare professionals on the safe and effective use of this new treatment.

This is in order to ensure optimal patient satisfaction and outcomes. The product is currently available in South Africa and various countries throughout the world – where Allergan will continue to work with international regulatory authorities to make this product more widely available to aesthetic practitioners and patients globally.

This demonstrates our ongoing commitment to delivering medical aesthetics treatments that physicians and their patients really want, which is not only convenient for patients and doctors, but is of high quality in its results and safety too.

*For medical regulatory purposes we are unable to mention the brand name of this treatment. Ask your doctor for more information on this new injectable skin product from Allergan*


1. Allergan Data On File INT/0444/2016 (2). July 2016.

2. Allergan Data On File INT/0513/2016. August 2016.

3. VYCROSS® Patent WO20040192222A2. 2004.

4. Juvéderm® VOLITE Directions For Use 73140JR10. November 2016.

5. Allergan Data On File INT/0912/2016. December 2016.

6. Allergan Data On File INT/0393/2016. Global Beauty Report. March 2016

A2 Disclaimer: This article is published for information purposes only, and should therefore not be taken as an endorsement or advertisement for any product or medical treatment –  nor should it be regarded as a replacement for sound medical advice. 

CURRENT Issue 21 – Mar 2017 (Autumn)

This article was written for and edited by the A2 team EXCLUSIVELY for the A2 Aesthetic & Anti-Ageing Magazine March Autumn 2017 Edition (Issue 21). 

A2 Magazine prints only four magazines each year – reporting seasonally on everything you need and want to know about aesthetics, anti-ageing, integrative medicine, quality and medical skin care, cosmetic dentistry and cosmetic surgery in South Africa – where to go, who to see, what to expect, something new and so much more! Never miss an edition – click here for more info about where you can buy the print and/or digital copy of A2 Magazine (including back copies).

To make use of any of our content for re-publishing, please contact for approval.




About Author

Rochelle Friedman

Rochelle is co-owner of A2 Aesthetic & Anti-Ageing Magazine - she looks after A2's Blog and the Sales & Marketing for the A2 Magazine. Follow her on twitter by clicking the birdy on the top right of this block.

Comments are closed.